to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

NCT05162937 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Axial Spondyloarthritis

Interventions

BIOLOGICAL: IL-17A antibody

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.